JHL Biotech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:Asia

Author(s):

Product Code:GDPH495735D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

34

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

JHL Biotech Inc (JHL Biotech) is a biologic medicines provider. The company offers cell line construction, process development, manufacturing, quality and regulatory services. It offers products such as biosimilar rituximab, biosimilar dornase alfa, biosimilar bevacizumab, biosimilar trastuzuma, biosimilar omalizumab, biosimilar pertuzumab and biosimilar denosumab. JHL Biotech has developed its own proprietary CHO-K1 cell line. The company offers antibody cloning, monoclonal antibody manufacturability and protein engineering, cell line development, cell culture process development, purification process development, formulation development and analytical assays. JHL Biotech also provides full-service contract manufacturing solutions to its partners, from cell line development through commercial active pharmaceutical ingredient manufacturing requirements. The company operates through its research center in Hsinchu, Taiwan; commercial GMP facility in Wuhan, China. JHL Biotech is headquartered in Zhubei, Taiwan.

JHL Biotech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

JHL Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

JHL Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

JHL Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 9

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

JHL Biotech Raises USD45.6 Million in Series C Financing 12

JHL Biotech Raises USD35 Million in Series B Venture Financing 13

JHL Biotech Raises USD 10 Million In Venture Financing 15

JHL Biotech Raises Funds Through Venture Financing 16

Private Equity 17

JHL Biotech Raises USD106 Million in Financing 17

Partnerships 19

Sanofi Enters into Agreement with JHL Biotech 19

BioLineRx Enters Into Co-Development Agreement With JHL Biotech 20

JHL Biotech Enters Into Agreement With Selexis For Drug Development 22

Equity Offering 23

JHL Biotech Raises USD80 Million in Private Placement of Shares 23

JHL Biotech to Raise Funds through Private Placement of Shares 24

Debt Offering 25

JHL Biotech Raises USD106 Million in Private Placement of Bonds 25

Acquisition 26

JHL Biotech Acquires 40% Stake in Wuhan-Based Bio-Medical Company for USD6.1 Million 26

JHL Biotech Inc-Key Competitors 27

JHL Biotech Inc-Key Employees 28

JHL Biotech Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Jun 13, 2018: JHL Biotech Announces Appointment of New Chief Financial Officer 30

Feb 01, 2018: JHL Biotech Shareholders Vote to Voluntary Delist from Taiwan Exchange 31

Jan 01, 2018: JHL Biotech Welcomes New Chief Medical Officer, Rong Chen 32

Dec 11, 2017: JHL Announces Its Proposed Voluntary Delisting from Emerging Stock Market of Taipei Exchange 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List of Figure

List of Figures

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

JHL Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 9


List of Table

List of Tables

JHL Biotech Inc, Pharmaceuticals & Healthcare, Key Facts 2

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

JHL Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

JHL Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 8

JHL Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 9

JHL Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

JHL Biotech Raises USD45.6 Million in Series C Financing 12

JHL Biotech Raises USD35 Million in Series B Venture Financing 13

JHL Biotech Raises USD 10 Million In Venture Financing 15

JHL Biotech Raises Funds Through Venture Financing 16

JHL Biotech Raises USD106 Million in Financing 17

Sanofi Enters into Agreement with JHL Biotech 19

BioLineRx Enters Into Co-Development Agreement With JHL Biotech 20

JHL Biotech Enters Into Agreement With Selexis For Drug Development 22

JHL Biotech Raises USD80 Million in Private Placement of Shares 23

JHL Biotech to Raise Funds through Private Placement of Shares 24

JHL Biotech Raises USD106 Million in Private Placement of Bonds 25

JHL Biotech Acquires 40% Stake in Wuhan-Based Bio-Medical Company for USD6.1 Million 26

JHL Biotech Inc, Key Competitors 27

JHL Biotech Inc, Key Employees 28

JHL Biotech Inc, Other Locations 29

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022